Search research articles
Contact Us
Filters
Showing results (11-20 of 21) with videos related to
Page
of 3
Sort By:
Journal of the American College of Cardiology
|
January 18, 2005
What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF)
Lars Gullestad, John Wikstrand, Prakash Deedwania, et al.
Journal of Cardiac Failure
|
April 29, 2009
The influence of renal function on clinical outcome and response to beta-blockade in systolic heart failure: insights from Metoprolol CR/XL Randomized Intervention Trial in Chronic HF (MERIT-HF)
Jalal K Ghali, John Wikstrand, Dirk J Van Veldhuisen, et al.
Journal of Cardiac Failure
|
December 20, 2005
Economic implications of extended-release metoprolol succinate for heart failure in the MERIT-HF trial: a US perspective of the MERIT-HF trial
J Jamie Caro, Kristin Migliaccio-Walle, Judith A O'Brien, et al.
European Journal of Heart Failure
|
May 27, 2010
Intermittent claudication as a predictor of outcome in patients with ischaemic systolic heart failure: analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure trial (CORONA)
Sally C Inglis, John J V McMurray, Michael Böhm, et al.
European Journal of Heart Failure
|
January 27, 2009
Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide
Hans Wedel, John J V McMurray, Magnus Lindberg, et al.
European Journal of Heart Failure
|
December 22, 2009
An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial
Paula K Lorgelly, Andrew H Briggs, Hans Wedel, et al.
Journal of the American College of Cardiology
|
October 2, 2010
Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre-specified substudy of CORONA (controlled rosuvastatin multinational study in heart failure)
John J V McMurray, Peter Dunselman, Hans Wedel, et al.
Journal of the American College of Cardiology
|
November 7, 2009
Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure)
John G F Cleland, John J V McMurray, John Kjekshus, et al.
Circulation
|
November 18, 2009
Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis
John J V McMurray, John Kjekshus, Lars Gullestad, et al.
The New England Journal of Medicine
|
November 7, 2007
Rosuvastatin in older patients with systolic heart failure
John Kjekshus, Eduard Apetrei, Vivencio Barrios, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 21) with videos related to
Sort By:
Page
of 3
Journal of the American College of Cardiology
|
January 18, 2005
What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF)
Lars Gullestad, John Wikstrand, Prakash Deedwania, et al.
Journal of Cardiac Failure
|
April 29, 2009
The influence of renal function on clinical outcome and response to beta-blockade in systolic heart failure: insights from Metoprolol CR/XL Randomized Intervention Trial in Chronic HF (MERIT-HF)
Jalal K Ghali, John Wikstrand, Dirk J Van Veldhuisen, et al.
Journal of Cardiac Failure
|
December 20, 2005
Economic implications of extended-release metoprolol succinate for heart failure in the MERIT-HF trial: a US perspective of the MERIT-HF trial
J Jamie Caro, Kristin Migliaccio-Walle, Judith A O'Brien, et al.
European Journal of Heart Failure
|
May 27, 2010
Intermittent claudication as a predictor of outcome in patients with ischaemic systolic heart failure: analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure trial (CORONA)
Sally C Inglis, John J V McMurray, Michael Böhm, et al.
European Journal of Heart Failure
|
January 27, 2009
Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide
Hans Wedel, John J V McMurray, Magnus Lindberg, et al.
European Journal of Heart Failure
|
December 22, 2009
An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial
Paula K Lorgelly, Andrew H Briggs, Hans Wedel, et al.
Journal of the American College of Cardiology
|
October 2, 2010
Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre-specified substudy of CORONA (controlled rosuvastatin multinational study in heart failure)
John J V McMurray, Peter Dunselman, Hans Wedel, et al.
Journal of the American College of Cardiology
|
November 7, 2009
Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure)
John G F Cleland, John J V McMurray, John Kjekshus, et al.
Circulation
|
November 18, 2009
Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis
John J V McMurray, John Kjekshus, Lars Gullestad, et al.
The New England Journal of Medicine
|
November 7, 2007
Rosuvastatin in older patients with systolic heart failure
John Kjekshus, Eduard Apetrei, Vivencio Barrios, et al.
Page
of 3